Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Acute Ischemic Stroke Drugs Industry?

In the last few years, the acute ischemic stroke drugs market has experienced consistent growth. The market size is expected to rise from $13.5 billion in 2024 to $14.07 billion in 2025, led by a compound annual growth rate (CAGR) of 4.3%. The expansion during the past period can be credited to factors such as the rising number of stroke cases, government initiatives and healthcare regulations, enhancing awareness and education, strategic alliances and collaborations, and an increasing elderly population.

The market for acute ischemic stroke drugs is projected to experience robust expansion in the coming years, escalating to a value of $17.62 billion by 2029 with a CAGR of 5.8%. This growth during the forecast period can be credited to factors such as the advent of novel therapies and an enriched drug pipeline, advancements in precision medicine and bespoke therapies, development of healthcare infrastructure worldwide, inflation in healthcare spendings, as well as the escalating use of telemedicine and remote patient monitoring. Key trends anticipated during the forecast period incorporate progress in thrombolytic therapies, creation of neuroprotective agents, breakthroughs in personalized medicine and biomarker study, telemedicine and remote monitoring surge, as well as collaborations and strategic alliances.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10049&type=smp

#Which Factors Are Currently Driving The Growth Of The Acute Ischemic Stroke Drugs Market?

An increase in chronic disease cases is predicted to fuel the expansion of the acute ischemic stroke drug market in the future. Chronic diseases, also recognized as non-communicable diseases, are conditions that persist for over a year and demand ongoing medical attention, limit daily activities, or both. Major causes of death and disability include chronic diseases such as heart disease, diabetes, and cancer. Acute ischemic stroke medications are primarily utilized in chronic diseases to minimize the likelihood of clot formation and strokes and restore cerebral blood flow. For example, in September 2022, the World Health Organization (WHO), a health agency based in Switzerland, reported that due to chronic diseases, approximately 41 million people die annually, accounting for 74% of all global deaths, and 17 million individuals die prematurely, before 70, from these diseases. It is projected that by 2025, about 164 million Americans, nearly 49% of the population, will have chronic diseases. Consequently, the escalating prevalence of chronic diseases is spurring the growth of the acute ischemic stroke drug market.

How Is The Global Acute Ischemic Stroke Drugs Market Structured In Terms Of Segments?

The acute ischemic stroke drugs market covered in this report is segmented –

1) By Type: Tablet, Capsule, Other Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Hospitals, Diagnostic Centers, Other Applications

Subsegments:

1) By Tablet: Immediate Release Tablets, Extended Release Tablets, Orally Disintegrating Tablets

2) By Capsule: Hard Shell Capsules, Soft Gelatin Capsules, Extended Release Capsules

3) By Other Types: Injectable Solutions, Intravenous (IV) Preparations, Inhalation Formulations

What Trends Are Currently Influencing Growth In The Acute Ischemic Stroke Drugs Market?

Leading companies in the acute ischemic stroke drug market are progressing with the creation of novel drug formulations, such as edaravone and dexborneol in a sublingual form, specifically for acute ischemic stroke. These sublingual formulations, designed to be absorbed quickly into the bloodstream when placed under the tongue, bring together the antioxidant and anti-inflammatory properties of both elements, enhancing the effectiveness of the treatment. For example, in October 2024, Simcere Pharmaceutical from China received breakthrough therapy designation for Sanbexin, a sublingual formula of edaravone and dexborneol, used in the treatment of acute ischemic stroke (AIS). This endorsement followed encouraging findings from the TASTE-SL phase 3 clinical trial (NCT04950920), which showed that 64.4% of patients who were treated with Sanbexin accomplished a modified Rankin Scale (mRS) score of =1 after 90 days, versus 54.7% in the placebo group. This therapy, deliverable even outside healthcare facilities, aims to lessen the incapacity and improve the prognosis for AIS patients.

Who Are The Main Participants Shaping The Acute Ischemic Stroke Drugs Market Landscape?

Major companies operating in the acute ischemic stroke drugs market include F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca plc, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Which Region Currently Holds The Largest Share In The Acute Ischemic Stroke Drugs Market?

North America was the largest region in the acute ischemic stroke drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10049&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model